SILO Pharma Inc (SILO)

NASD · Healthcare · Biotechnology · USA

SILO Pharma Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

SILO Pharma is a developmental stage biopharmaceutical and cryptocurrency company creating novel drug therapies for psychiatric and neurological disorders. Its product candidates employ intranasal formulations and implant technologies based on conventional and psychedelic compounds, developed through academic partnerships with Columbia University and the University of Maryland, Baltimore. The company also holds cryptocurrency assets.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the SILO Pharma Inc stock.

Our verdict on SILO

Undervalued: intrinsic value $3.84 per share, market price $1.71, margin of safety 55.5% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $3.84; the price of $1.71 is 55% below that value.

ETFs with the most weight in SILO

More on SILO

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than SILO in Biotechnology

4 more in this industry show a wider margin of safety.

Is SILO undervalued or overvalued?

SILO is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $3.84; the price of $1.71 is 55% below that value.

What is the intrinsic value of SILO?

$3.84 per share (as of the 2026-11-17 close), against a market price of $1.71. That is a margin of safety of 55.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.